The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous ...
Recursion Pharmaceuticals Inc. stocks have been trading down by -4.08 percent after cautious reaction to its latest AI ...
Cathie Wood's ARK Invest executed a $22 million healthcare portfolio rotation on Monday, selling approximately $18 million of ...
Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Recursion Pharmaceuticals Inc. surged as breakthrough AI-driven drug discovery progress fueled bullish sentiment, and stocks ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...
ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on ...
Investor's Business Daily on MSN
Stock market today: Dow, S&P 500 rally; Cathie Wood buys this stock amid 56% dive
The Dow Jones index rises on the stock market today as Treasury yields fall. AMD, Nvidia and Tesla rally. An AI stock tests ...
Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) registers a bigger fall than the market: Important facts to note
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.70, marking a -1.2% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.77%. On ...
ARK Invest sold $17.1M in Twist Bioscience shares and purchased Recursion Pharmaceuticals, Intellia Therapeutics, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results